Back to search

National and Kapodistrian University of Athens

Evaluation of novel nucleoside analogues for lung cancer treatment: an approach based on metronomic chemotherapy

Abstract

dc:description

Lung cancer presents a contemporary global pandemic being responsible for a 18,4% of deaths for both sexes worldwide in 2018 , as well as an estimated 13% of cancer related cases and 134,720 deaths in US in 2020 . Non-Small Cell Lung Cancer (NSCLC), being the most prevalent form, represents 80% of the total reported cases. This high percentage is due to the late-stage diagnosis, limiting the median survival time up to 5 years. Staging lung cancer is based on whether the cancer is advanced locally or has spread from the lungs to the lymph nodes or other organs. Because of the size of the lungs, tumors can grow for a long time before they can be detected. Even when symptoms, like coughing and fatigue occur, people think they are caused by tuberculosis and chronic bronchitis. For this reason, early-stages of lung cancer (stages I and II) are difficult to detect. Most people with lung cancer are diagnosed at stages III (a and b) and IV.No one can deny that in the last decade, encouraging progress has been reported withthe development of personalized molecular screenings leading to more targetedtherapies which if combined with immunotherapies could possibly lead to a morecurative option. However, taking into account the urgent need for the restriction oftumor’s progression and metastasis, clinicians prefer to turn to traditional chemotherapy, as it focuses directly on the disruption of the uncontrolled and abnormal proliferation of cancer cells.Maximum Tolerated Dose chemotherapy (MTD) is the most preferred treatment modality for NSCLC and it is based on the highest acceptable dose of a drug or treatment that does not cause side effects. Though effective at first, after several cycles of drug administration, this approach results in the appearance of cancer resistance to the drug, as well as increases in acute toxicity causing patients to ultimately experience unpleasant side effects. Gemcitabine is a commonly used nucleoside analogue for the chemotherapeutic treatment of NSCLC, which inhibits the cell cycle through DNA polymerase inhibition and effectively prevents tumor growth and expansion. Although gemcitabine is approved for the treatment of various cancer types including NSCLC, its efficacy is still limited. A major disadvantage is its lack of efficiency, which is caused by rapid metabolic inactivation, as well as the induction of cancer resistance. To overcome these drawbacks, metronomic chemotherapy (MTR) is presented to constitute an alternative approach to fight cancer. MTR, which relies on the frequent administration of the chosen drug, at lowdoses, with no prolonged drug-free breaks, is a multi-targeted therapy, as it inhibits tumor angiogenesis, modulates immunity pathways, effects tumor initiating cells and induces tumor dormancy exceeding the toxicity of traditional standard-dose chemotherapy. Our goal is to investigate the effect of MTR on NSCLC, both in vitro and in vivo, using an orally administered nucleoside analogue, OralGem, which is a prodrug of gemcitabine with ultimate goal to cover patients' needs as far as their compliance and quality of life are concerned.Alterations in the angiogenic profile around the tumor site were detected, as well as the recruitment of immune populations limiting inflammation and boosting immune surveillance. This alternative chemotherapeutic strategy also favored OralGem revealing more promising pharmacokinetic properties, as well as minimized blood and thymus toxicity compared to traditional MTD gemcitabine. However, MTR OralGem alone could not reach the efficacy offered by MTD gemcitabine, whilst showing improvements compared to the untreated groups of animals. For this reason, MTR OralGem was co-dosed with anti-PD1, maintaining its effect on tumor microenvironment, but mainly leading to improved efficacy against lung cancer.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2021

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Skavatsou, Eleni
  • Σκαβάτσου, Ελένη

Subjects

dc:subject × 26

Rights

Language dc:language
eng

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/50570

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Skavatsou, Eleni; Σκαβάτσου, Ελένη. Evaluation of novel nucleoside analogues for lung cancer treatment: an approach based on metronomic chemotherapy. National and Kapodistrian University of Athens, 2021. http://hdl.handle.net/10442/hedi/50570